Translational Efficacy & Toxicity Studies
Our Therapeutic Focus
Biocytogen’s Preclinical Services Division has established comprehensive in vivo and in vitro pharmacology capabilities and provides world-class services to our customers. Our team has significant expertise in testing novel therapeutics for immuno-oncology, oncology, and autoimmune/ inflammatory disease applications.
At the foundation of these in vivo efficacy studies are a large collection of genetically humanized mouse models for immune checkpoint inhibitors and cytokine/cytokine receptors, our highly immune-deficient B-NDG mice and their variants, including human immune reconstituted models using human PBMC and CD34+ engraftment, CDX (cell line-derived xenograft) models, and engineered cell line models.
Services We Offer
We assess the efficacy of a wide range of biologics such as antibodies, vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
Complementary to our in vivo capabilities, our in vitro pharmacology services include immune cell profiling (e.g. tumor infiltrating lymphocytes (TIL) analysis), cytokine profiling, primary T, NK, and macrophage cell-based functional assays such as T cell activation, mixed-lymphocyte reaction (MLR), T cell cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), target binding, receptor occupancy (RO), cell proliferation and cell death, and cell reporter assays.
Cancer immunotherapy is one of the most promising anti-cancer therapeutic breakthroughs in recent years. Biocytogen provides immuno-oncology and preclinical oncology services, offering the highest quality and the most comprehensive collection of genetically humanized immune-checkpoint mouse models to accelerate the discovery and development of therapeutics. In addition to immuno-oncology services, Biocytogen provides robust human immune cell-engrafted mouse models. Our CDX mouse models can be used to support preclinical efficacy investigation of immuno-oncology and oncology drugs. Our preclinical oncology services can help drug discovery via multiple modalities.
We have successfully supported our pharmaceutical and biotech customers in evaluating the efficacy of multiple biologics (including monoclonal antibodies, bispecific antibodies, and recombinant proteins), peptides, small molecules, CAR-T cell therapy, and oncolytic viruses. Our Preclinical Services Division has completed over 500 drug evaluation projects for more than 200 partners worldwide. We have also successfully assisted our customers in IND applications. Supported by Biocytogen’s large-scale generation of new animal models and advanced gene editing technology, our Preclinical Services Division will continue to deliver high-quality, timely and cost-effective services, provide comprehensive and accurate data, and facilitate drug discovery and development for our customers worldwide.
Read on for more details and case studies: